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Abstract
Background: Human African trypanosomiasis is a severely neglected vector-borne disease that is always fatal if untreated. In
Tanzania it is highly focalised and of major socio-economic and public health importance in affected communities.
Objectives: This study aimed to estimate the public health burden of rhodesiense HAT in terms of DALYs and financial costs
in a highly disease endemic area of Tanzania using hospital records.
Materials and Methods: Data was obtained from 143 patientsadmitted in 2004 for treatment for HAT at Kaliua Health Centre,
Urambo District. The direct medical and other indirect costs incurred by individual patients and by the health services were
calculated. DALYs were estimated using methods recommended by the Global Burden of Disease Project as well as those used
in previous rhodesiense HAT estimates assuming HAT under reporting of 45%, a figure specific for Tanzania.
Results: The DALY estimate for HAT in Urambo District with and without age-weighting were 215.7 (95% CI: 155.3–287.5)
and 281.6 (95% CI: 209.1–362.6) respectively. When 45% under-reporting was included, the results were 622.5 (95% CI:
155.3–1098.9) and 978.9 (95% CI: 201.1–1870.8) respectively. The costs of treating 143 patients in terms of admission costs,
diagnosis, hospitalization and sleeping sickness drugs were estimated at US$ 15,514, of which patients themselves paid US$
3,673 and the health services US$ 11,841. The burden in terms of indirect non-medical costs for the 143 patients was
estimated at US$ 9,781.
Conclusions: This study shows that HAT imposes a considerable burden on affected rural communities in Tanzania and
stresses the urgent need for location- and disease-specific burden estimates tailored to particular rural settings in countries
like Tanzania where a considerable number of infectious diseases are prevalent and, due to their focal nature, are often
concentrated in certain locations where they impose an especially high burden.
Citation: Matemba LE, Fe `vre EM, Kibona SN, Picozzi K, Cleaveland S, et al. (2010) Quantifying the Burden of Rhodesiense Sleeping Sickness in Urambo District,
Tanzania. PLoS Negl Trop Dis 4(11): e868. doi:10.1371/journal.pntd.0000868
Editor: Joseph Mathu Ndung’u, Foundation for Innovative New Diagnostics (FIND), Switzerland
Received June 8, 2009; Accepted October 1, 2010; Published November 2, 2010
Copyright:  2010 Matemba et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The authors acknowledge the financial support from Animal Health Programme (AHP) of the UK Department for International Development (DIFD) and
the World Health Organization (WHO), which made this work possible. The funders had no role in study design, data collection and analysis, decision to publish,
or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: sue.welburn@ed.ac.uk
Introduction
Sustainable solutions to most of the neglected tropical infections,
which include human African trypanosomiasis (HAT) [1], remain
illusory in most of the poor rural communities living in third world
countries. Whilst significant, but still insufficient, recourses have
been directed towards research and control of those diseases which
are capable of making sizeable contributions to global pandemics
such as HIV, Avian influenza, H5N1 and most recently H1NI,
political bias and a myriad of other factors have led woefully
inadequate resources being allocated to dealing with less high
profile diseases [2]. Poor countries are thus left alone struggling to
control a handful of endemic ‘neglected’ infectious diseases [3].
Many of these diseases occur in clusters within the same
individuals the so-called ‘‘polyparasitic’’ [3,4] and often alongside
other conditions, including the major killer diseases [5]. Frustrat-
ingly, amongst the neglected tropical diseases, some diseases are
more neglected than others both locally and internationally.
Furthermore, many neglected disease are also zoonotic [6],
affecting both humans and animals and imposing a dual burden
on human and animal health. As such these diseases have a major
impact on rural livelihoods by contributing towards the increasing
the level of poverty in most of these communities, which are
already poor. Sleeping sickness or human African trypanosomiasis
(HAT) is a classic example of a neglected disease. The ‘acute’ form
of HAT found in eastern Africa and caused by Trypanosoma brucei
rhodesiense is zoonotic and needs to be addressed from human and
animal perspectives. Some authors [7,8] have notably argued that
www.plosntds.org 1 November 2010 | Volume 4 | Issue 11 | e868the burden of the rhodesiense form of HAT can be significantly
reduced by treating domestic livestock reservoirs as this can play
an important role in controlling HAT in humans. This has
significant cost implications for rural medical and veterinary
services.
The public health burden for HAT has been estimated at
1,609,000 DALYs with 50,000 annual deaths [9], although there
are many methodological and data issues that deserve greater
consideration when making such estimates for HAT [10]. The
HAT figure none-the-less seems small when compared with the
standard (discounted at 3% and age-weighted) DALY burden in
Africa of (46.7 million due to HIV/AIDS (Human immunodefi-
ciency virus/Acquired Immune Deficiency Syndrome), 30.9
million from malaria and 10.8 million from tuberculosis [8].
However, HAT, like many other neglected diseases, is highly
focalized, and its burden therefore needs to be considered in
relation to the affected localities. There has been a dramatic
reduction in the number of reported HAT cases, which declined to
15 and to 17,000 cases per year [11] in the mid-2000s from nearly
40,000 at the end of the 1990s, but major challenges still exist in
predicting future disease trends. With only six years remaining to
the year targeted by World Health Organization (WHO) for HAT
elimination, the disease situation is still unclear in about one third
of the countries where it is endemic [11]. Accurate estimates of
incidence and effective control of HAT, especially of the chronic
West and Central African form caused by T. b. gambiense, depend
on active surveillance which is expensive and requires a high level
of organization. Among vector-borne diseases in Africa, HAT
ranks second for mortality and fourth in terms of disability
adjusted life years (DALYs), but the fact that this is a severely
under-reported disease [12] has largely prevented accurate
assessment of its true burden.
In the United Republic of Tanzania, HAT is a disease of major
public health and socio-economic importance in affected rural
communities, where it continues to impose a serious threat to the
4–5 million people exposed to it. Between 1996 and 2006, 2748
cases were reported in Tanzania [11,13]. This figure represents an
average of about 250 cases of T. b. rhodesiense reported annually,
and over 40% of the global total. More than 95% of the cases were
reported from just three regions in the western part of the country.
Tanzania still has several active HAT foci which have been
persistent for over 80 years. The disease, which was effectively
controlled in early 1960s, made a dramatic re-emergence in some
parts of the country during the 1990s [14,15], due to a lack of
adequate and sustained control activities. Here we attempt to
quantify the burden of zoonotic HAT imposed in rural Tanzania
in recent years.
Materials and Methods
Between 2000 and 2007, five rural districts of Tanzania,
Kigoma, Kasulu, Kibondo, Urambo and Mpanda, all located in
the western part of the country, reported cases of sleeping sickness.
Out of the five districts, Urambo was purposefully selected for two
main reasons; first it recorded the highest number of cases, and
second it had the best record-keeping for HAT. Thus, our study
relates to the burden of HAT in the high incidence district of
Urambo.
Study area and population
Urambo District (Figure 1) is situated in Tabora region, which is
in the western part of the country between latitude 4u 000–5u 530S
and longitude 30u 009–32u 370 E. It occupies 25,995 km
2 with a
total population of 369,329 in 2002 [16]. The district shares a
common border with Mpanda, Kigoma rural and Kasulu districts
where HAT is also endemic. The predominant ethnic groups are
Nyamwezi and Sukuma with some Fipas. Kinyamwezi is the most
widely spoken language, although Swahili, the national language,
is also used. Subsistence farming is widely practiced, the main
crops being tobacco, rice and maize.
Data collection
All the patients included in the present study were diagnosed
and treated in Kaliua Health Centre. Three cases werediagnosed
during active surveillance activities carried out in Urambo
district, which were also referred to Kaliua for treatment. The
remaining patients presented passively. Kaliua is a missionary
health facility that was selected by the district health authorities
to manage all HAT cases in Urambo district, due to its location.
It is within the disease catchment area and is easy accessible by
train to patients from all affected villages. Information about
HAT patients diagnosed and treated in Kaliua between 2000 and
2007 was obtained from hospital registers. Patient records were
categorized by sex, age cohort, stage of the disease, dates of
admission and discharge, initial and final diagnosis; treatment
provided (this was done with the intention of confirming the stage
of the disease), duration of hospitalization and finally the
outcome of the disease. The distinction between first/early stage
patients (where the parasite is circulating in the blood and lymph
system) and second/late stage (where it has passed through the
blood brain barrier into the cerebro- s p i n a lf l u i d )d e t e r m i n e sw h a t
treatment patients are given. For T. b. rhodesiense, first stage
patients receive Suramin and second stage patients Melarsoprol
[17]. It was not possible to obtain disease stage data for 22 of the
patients (as this was not recorded by the care team and further
records were unavailable). However, all these un-staged patients
recovered and were discharged from the hospital. Therefore,
using the conservative assumption that there are fewer non drug-
related complications and there is no increased non drug-related
mortality in the early stage of the disease, the 22 patients were
assumed to be early stage.
Author Summary
Sleeping sickness (human African trypanosomiasis - HAT) is
a disease transmitted by tsetse flies and is always fatal if
left untreated. The disease occurs in foci affecting poor
communities with limited access to health service provi-
sion and as such the disease is often left undiagnosed,
mistaken for more common afflictions. Even if diagnosed,
sleeping sickness is costly to treat, both for health services
and patients and their families in terms of costs of
diagnosis, transport, hospital care, and the prolonged
period of convalescence. Here we estimate the health
burden of the ‘‘acute form’’ T. b. rhodesiense sleeping
sickness in Urambo District, Tanzania in terms of Disability
Adjusted Life Years (DALYs), the yardstick commonly used
by policy makers to prioritize disease management
practices, representing a year of healthy life lost to disease.
In this single district, the burden of the disease over one
year was estimated at 979 DALYs and the estimated
monetary costs to health services for the 143 treated
patients at US$ 11,841 and to the patients themselves at
US$ 3,673 for direct medical costs and US$ 9,781 for
indirect non-medical costs. Sleeping sickness thus places a
considerable burden on the affected rural communities
and health services.
Burden of HAT in Tanzania
www.plosntds.org 2 November 2010 | Volume 4 | Issue 11 | e868Figure 1. Map of Tanzania showing the location of districts affected by sleeping sickness including Urambo district.
doi:10.1371/journal.pntd.0000868.g001
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Population, incidences and number of deaths were grouped into
5 year age cohorts for ages 5 to 79, and into ,1 year, 1–4 years,
and 80+ years. Data were manipulated in Microsoft Excel 2003
and analysed in a fully stochastic framework run using the @Risk
software package (Palisade, Newfield, NY, USA version 5.0), as
described in [7]. The methodology captures both uncertainty and
annual variability in the estimates. Both life expectancy data and
the template for the DALY calculation were obtained from WHO
website (http:/www.who.int/evidence). The life table used in this
study was Tanzania-specific [8].
The DALYs calculations for HAT in Tanzania used an adapted
stochastic approach [8]; 10,000 Monte-Carlo simulations were run
using, at each iteration, input values drawn from the data of the
same year per iteration. Final output data was provided as means
with 95% confidence intervals.
Disability Adjusted Life Years (DALYs) for T. b. rhodesiense
HAT
The total DALY score for each cause-age-sex group were
calculated as the sum of non-fatal burden (years of life lived with
disability - YLD) and the burden of premature mortality (years of
life lost - YLL). To calculate the DALY score for T. b. rhodesiense
HAT in Urambo, we applied a 3% discount rate, both with and
without age-weighting. The information required for DALY
estimations is shown in Table 1. The population data for Urambo
District used in the current calculations was projected for the year
2004 from the 2002 Tanzania population and housing census data
by applying the estimated annual population growth rate of 4.8%
per annum [16] using the standard compound growth rate
formula to obtain an estimate of 406,235.
Years of Life Lost (YLL)
To calculate YLL for Urambo, standard global burden of
disease (GBD) methods were followed, using the age categories
described above. All other information required for the calculation
is shown in Table 1. The total number of reported deaths and
estimated under-reporting for Tanzania are described elsewhere
[18]; we used under-reporting rates of 0% (no under-reporting),
and the figure 45% under-reporting (that is for every 100 reported
cases, a further 45 remained un-reported), which had already been
derived [16].
Years Lost due to Disability (YLD)
As previously published [8], we use a disability weighting of 0.21
for early stage HAT and 0.81 for late stage episodes based on
standard definitions [19]. Previous DALY estimates for T. b.
rhodesiense used a weighting of 0.35 (originally devised for T. b.
gambiense infection); we also ran our model with this value, for
comparison. Although long term effects, sequelae, from HAT are
known to exist [20] the data to support a calculation of these for
this sample did not exist and therefore sequelae were not included.
Estimating Disability Adjusted Life Years in the absence
of the HIV/AIDS pandemic
AIDS has a significant impact on burden of disease estimates. It
is estimated that life expectancy for Tanzanians fell from 54 years
in 1990 to 45.9 years in 2004 [21] and that the incidence of AIDS
will reduce life expectancy in Tanzania by 17% during 2000–05,
by 14% during 2010–2015 and by 7% during 2045–50 [22]. The
disease that has already increased mortality by 11 percent has also
resulted in welfare losses equivalent to 47.2 percent of GDP [23].
In realizing this importance, if we assume that HIV pandemic did
not occur, then the burden due to most of diseases would probably
have been different from what we observe today. In an attempt to
capture and compare this component of calculations, we decided
to recalculate DALYs using the same set of data but with the
assumption that HIV pandemic did not occur. We therefore re-
calculated the DALY score using the life expectancy of
Tanzanians for the year 1990, when HIV infection was not very
severe in the country.
Estimating the direct costs of hospitalisation at the
health facility
The costs to the health system per HAT patient were estimated
from four components i) the product of the total recorded hospital
stays due to HAT in days multiplied by an estimated daily cost for
hospital services plus ii) the estimated cost of diagnosing HAT
patients plus iii) a value for the drugs used to treat HAT less iv) the
amounts that patients paid towards these costs. The total number
of days of hospitalisation due to HAT in 2004 at the Kaliua Health
Centre was 3601, or a little more than 25 days per parasitolog-
ically confirmed HAT patient. Kaliua Health Centre being a
missionary hospital, patients are only charged a nominal amount
of Tanzanian Shillings (TZS) 1000 (approximately US$ 1), per
every patient per night bed occupancy [24], plus a one off
payment of TZS 500 (approximately US$ 0.5) for initial laboratory
tests on admission. The true cost of these tests would be higher.
Here we assume that, in line with the figures cited in [17] the total
cost would be at least US$1. This hospitalisation charge is also low,
compared, for example with costs for Uganda [7] which were
estimated at US$ 2 per day’s hospitalisation for HAT, in itself a
Table 1. Information required for the estimation of disability adjusted life years (DALYs) for rhodesiense sleeping sickness.
DALY component Type of data required Source of data used in this study
Years of Life Lost (YLL) 1) Number of deaths Health facility records of case fatality, estimates of under-reporting.
2) Life expectancy at birth Life tables obtained from WHO website, based on African standard life tables specific for
Tanzania for the year 2004, with life expectancy at birth of 48.0 years which was assumed to
be representative for the population of Urambo district for the year 2004.
3) Distribution of deaths
according to age
Health facility records, summarized for each age group (with and without age weighted case
fatality rate and under-reporting rate) using methods developed for Uganda [12].
Years Lost due to Disability (YLD) 4) Disability weighting From rhodesiense sleeping sickness records as per Murray (1994) methods and also using
expert opinion.
5) Duration of illness Health facility records excluding post treatment duration.
6) Age weighting Health facility records of productivity of different age groups.
doi:10.1371/journal.pntd.0000868.t001
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true cost of hospitalisation, half of which was covered by the
patients’ nominal fee. Thus we conservatively assumed that the
fees charged to patients for hospitalisation and admission covered
half the actual cost to the health services. Charges for other
services such as additional laboratory investigations and treatment
incurred by individual patients (depending on the clinical
presentation and severity of the condition) were not included in
this part of the study. The local currency was converted using the
2004 rates taken from the Bank of Tanzania, during which US$
1was equivalent to TZS 1000.
Turning to drugs, all the drugs used to treat HAT cases in
Tanzania are provided free of charge by WHO. Drugs are bought
by WHO from the manufacturers at a greatly subsidised price. The
Tanzanian Ministry of Health and Social Welfare is then
responsible for making these drugs available to all treatment
centres. Finding an appropriate value for the drugs is thus complex,
so the compromise of using the costs at the levels paid by WHO is
used here. Accordingly the costs for the 30 early and 113 late stage
cases were estimated and added to the costs, using the rate of US$
35 for early and US$ 63 for late stage estimated by WHO.
Other additional costs were difficult to quantify and were
excluded from the current estimates since they vary greatly
according to each individual presentation. These include drugs to
treat individual presentations such as fever, anaemia, pain, adverse
drug events and all concomitant conditions. However, transport to
and from the hospital, living costs during hospital stay and costs to
cover living expenses for one accompanying person were regarded
as patients’ non-medical or indirect costs and were estimated. All
HAT patients require assistance with daily living activities, such as
meal preparation, shopping and housework.
Costs borne by patients
The costs borne by patients were firstly, the direct medical costs in
terms of the US$ 1 fee per day’s hospital stay and the US$ 0.50
admission fee and secondly indirect, non-medical costs. These were
estimated in terms of transportation and living costs incurred by each
patient during the entire duration of hospitalization. Data used in this
part of study were provided by relatives of the patients who were
admitted at Kaliua Health Centre during the course of the study and
also patients who recovered from HAT who werefollowed up in their
homes in a separate study conducted towards the end of 2007. Travel
costs were estimated using reasonable rail fares (roads in most of the
disease endemic villages are impassable during the rainy season and
the only reliable means of transport is through the railway system; all
HAT-affected villages were accessible by train).
The village of origin for all 143 patients were obtained from the
hospital register. Standard travel costs were estimated based on the
information provided by both patient and relatives, the majority
reported that they travelled on the third class coach; therefore
third class fare information for all destinations was obtained from
the station master at Kaliua railway station. The basis for the
estimates is shown in Table 2. The 143 patients spent a total of
US$ 479.50 on transport from their home village to Kaliua Health
Centre. This is equivalent to US$ 3.35 per patient per single trip to
Kaliua, or US$ 6.70 for a return trip. HAT patients also require
assistance with food preparation and personal care, meaning that
each patient required one accompanying adult person (over 18
years) for TZS 600 per day to buy meals for their relative from a
local restaurant. Since the majority of patients were from villages
located far from Kaliua we estimated this using the modest costs of
ordering food from a nearby restaurant. We assumed that the
accompanying person spent the same amount per day on meals.
The living costs for an accompanying person were estimated at
the rate TZS 500 per person per night spent in a local guesthouse
(US$ 0.50). All other expenses such as costs required for general
care and personal hygiene or any other basic needs for the patient
were not included in the current estimates as they varied from one
patient to another.
Ethical statement
Permission to conduct this study in Tanzania was obtained from
the Research Ethics Sub-Committee of the National Institute for
Medical Research as well as the District Health Authorities of
United Republic of Tanzania.
Results
Between 2000 to 2007, a total of 521 HAT cases were
diagnosed and treated at Kaliua Health Centre as follows; 29
patients were diagnosed in 2000, 38 cases in 2001, 58 cases in
2002, 98 cases in 2003, 143 cases in 2004, 83 in 2005, 33 in 2006
and 39 cases in 2007. The highest number of cases of HAT was
observed in the year 2004, and this year was selected for the study.
As an example, some of the other conditions diagnosed at Kaliua
for the year 2004 are shown in Figure 2.
T. b. rhodesiense HAT Disability Adjusted Life Years
(DALYs)
The overall DALYs burden due to T. b. rhodesiense HAT in
Urambo is the sum of all the YLLs and YLDs estimated from the
model using annual age specific data for both reported and
estimated (at 0.45 (95% CI: 0.36–0.53) unreported deaths, and
non age weighted discounted YLL (DYLL) as shown in Table 3.
The model also estimated that premature mortality due to HAT
was responsible for 190.1 (95% CI: 17.5–250.0) years of life if we
assume that all HAT cases were reported. When 45% under-
reporting with age weighting and without age weighting are taken
into account then HAT was responsible for 1030.5 (95% CI:
201.9–1747.3) and 610.8 (95% CI: 17.5–938.4) YLLs respectively.
Table 3 shows the results of years of life lost for each age group.
The model also estimated that T. b. rhodesiense HAT was
Table 2. Non-medical indirect costs incurred per individual sleeping sickness patient attending Kaliua health centre estimated in
US$.
Patient US$ Accompanying person US$ Total per patient US$
Travel 6.7 6.7 13.4
Meal 15.0 15.0 30.0
Accommodation 0.0 25.0 25.0
Total 21.7 46.7 68.4
doi:10.1371/journal.pntd.0000868.t002
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disability in Urambo district, when no age weighting and no
under-reporting was applied. When age weighting was added then
this result increases to 25.5 (95% CI: 0–67.4) YLDs. A full
breakdown of age specific years lived with disability in Urambo
district is shown in Table 4.
From the above YLL and YLD results, if we assume that all
HAT cases were reported and no age weighting was applied then
the DALY score for Urambo was 215.7 (155.3–287.5), when age
weighting is applied the result increased to 281.8 (95% CI: 209.1–
362.6). If 45% under-reporting and no age weighting was applied
then the result was 622.5 (95% CI: 155.3–1098.9), however, when
Figure 2. Recorded incidence of selected health conditions at Kaliua Health Centre from January to December 2004.
doi:10.1371/journal.pntd.0000868.g002
Table 3. Years of Life Lost (YLL) due to T.b. rhodesiense sleeping sickness in Urambo, Tanzania.
Age of
onset
(years)
Total
population
Total
reported
cases
Total
reported
deaths
Total un-detected
deaths with 45%
under-reporting
YLLs with 0%
under-reporting
and no age
weighting
YLLs with 0%
under-reporting
and with age
weighting
YLLs with 45%
under-reporting
and no age
weighting
YLLs with 45%
under-reporting
and with age
weighting
0–4 14,547 5 0 2.25 (1.8–2.7) 0 0 27.7 (0–75.1) 33.8 (0–90.9)
5–14 63,082 15 1 6.75 (5.4–8.1) 147.5 202 166.1 (147.5–209.1) 226.8 (202.0–284.1)
15–29 104,073 49 3 22.1 (17.6–26.5) 31.6 (0–64) 41.9 (0–85.3) 208.8 (0–399.6) 281.9 (0–541.8)
30–44 26,376 34 1 15.3 (12.2–18.4) 9.1 (0–19.5) 10.4 (0–23.8) 83.0 (0–196.5) 96.5 (0–228.5)
45–59 53,346 23 1 10.4 (8.3–12.4) 3.6 (0–14.9) 3.4 (0–14.6) 49.1 (0–105.5) 43.4 (0–91.2)
60–69 11,240 9 1 4.1 (3.2–4.9) 1.1 (0–8.5) 0.7 (0–5.6) 21.4 (0–42.1) 15.3 (0–30.8)
70–79 6711 5 0 2.25 (1.8–2.7) 0 0 6.0 (0–14.6) 3.5 (0–8.7)
80+ 3542 3 0 1.4 (1.1–1.62) 0 0 2.3 (0–7.0) 1.1 (0–3.3)
Total 405,636 143 7 64.4
(51.5–77.2)
192.9
(147.5–250.0)
258.3
(202.0–322.5)
564.4
(147.5–966.4)
702.4
(202.0–1200.3)
All values are means with lower and upper 95% confidence intervals in brackets as obtained from 10,000 Monte-Carlo simulations derived from the 2000–2007 Urambo
HAT data.
doi:10.1371/journal.pntd.0000868.t003
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score was 978.9 (95% CI: 201.9–1870.8). Age specific DALY
scores are detailed in Table 5. If a disability weight of 0.35 is
applied (25) then the DALY burden would be 573.5 (95% CI:
147.5–1002.1).
If we assume that DALY burden were estimated in the absence
of AIDS pandemic, as shown in Table 6, then the DALYs with no
under-reporting would have been 205.1 (95% CI: 147.5–273).
When 45% under-reporting and no age weighting was applied,
then the DALY burden would have increased to 585.7 (95% CI:
175–1029.8) and 761.6 (209.3 –
Total costs of hospitalisation for HAT patients and health
services
Between January and December 2004, 143 T. b. rhodesiense HAT
cases were parasitologically confirmed at Kaliua Health Centre, out
of them 30 cases were early while the other 113 were late stage
sleeping sickness cases. These patients stayed in hospital for a total of
3601 days, resulting in mean hospital stay per patient of 25 days.
Following the discussion on costs above, the costs of hospital stays
were estimated for all 143 patients at the conservatively low rate of
TZS 2000 (US$ 2) per patient per night giving a cost of US$ 7202,
and an estimated US$ 1 per patient for initial diagnosis, coming to
US$ 143. Applying as the cost of the drugs to treat the disease the
values estimated by WHO, 30 early stage and 113 late stage patients
would cost US$ 1050 and US$ 7119 respectively to treat, Thus the
total cost to the health services, including WHO, would be estimated
at US$ 15,514. Of this, the patients themselves would contribute US$
3601 (US$1 per day’s hospitalisation) plus US$ 71.50 (US$0.50
admission fee per patient), making a total of US$. 3672.50
Subtracting this sum, the net cost to the health services would thus
be US$ 11,841.50. These figures should be regarded as low estimates.
Indirect costs incurred by HAT patients for the period of
their stay in hospital
Apart from the costs incurred by every individual patient on
admission costs, each patient required an additional of US$ 63.40
which were indirect non-medical costs to cover their travel costs,
Table 4. Years of Life Lived with Disability (YLD) due to T.b. rhodesiense HAT in Urambo.
Age of onset
(years) Total population Total reported cases
YLD for recovered cases
(early and late stage) and
no age weighting
YLD for recovered cases
(early and late stage)
and with age weighting
0–4 14,547 5 0.8 (0.7–0.8) 0.3
5–14 63,082 15 2.8 (0.2–6.7) 3.1 (0.3–7.5)
15–29 104,073 49 2.4 (0.2–4.8) 3.6 (0.2–7.3)
30–44 26,376 34 7.0 (1.8–14.8) 9.6 (2.5–20.4)
45–59 53,346 23 8.4 (1.6–16.9) 8.9 (1.8–18.0)
60–69 11,240 9 7.1 (2.1–14.0) 5.7 (1.6–11.2)
70–79 6711 5 6.8 (0–24.0) 4.2 (0–14.8)
80+ 3542 3 1.3 (0–3.1) 0.6 (0–1.4)
Total 405,636 143 37.2 (12.7–65.9) 39.4 (13.4–64.3)
Disability weights of 0.21 (approximating to a limited ability to perform most activities in one of the following areas: recreation, education, procreation or occupation
[24]) and 0.81 (needing assistance with instrumental activities of daily living such as meal preparation, shopping and housework [24]) were used for the early and late
stage cases respectively in these calculations.
The results are expressed as mean values with 95% confidence intervals in brackets, these were obtained from 10000 Monte-Carlo simulations of the data derived from
2000–2007 Urambo sleeping sickness cases.
Note that column totals are independently modeled and may therefore not exactly match age-specific output summaries.
doi:10.1371/journal.pntd.0000868.t004
Table 5. Disability Adjusted Life Years (DALYs) due to T.b.rhodesiense sleeping sickness in Urambo, Tanzania.
Age of onset
(years)
DALYs with 0%
under-reporting and
no age weighting
DALYs with 0%
under-reporting and
with age weighting
DALYs with 45%
under-reporting and
no age weighting
DALYs with 45% under-
reporting and with age
weighting
0–4 0.8 (0.7–0.8) 0.3 28.5 (0.7–75.9) 34.1 (0.3–91.2)
5–14 150.3 (147.7–154.2) 205.1 (202.2–209.5) 180.4 (147.7–218.7) 245 (202.2–295.4)
15–29 35.2 (0.2–64.4) 46.9 (0.2–85.9) 222.4 (0.2–403.2) 300.7 (0.2–547.1)
30–44 14.8 (1.8–34.0) 18.5 (2.5–43.9) 86.4 (1.8–212.0) 102.1 (2.5–249.7)
45–59 11.9 (1.6–30.5) 12.2 (1.8–30.4) 57.4 (4.3–122.1) 52.3 (4.6–108.8)
60–69 8.2 (2.1–19.6) 6.4 (1.6–14.5) 28.5 (9.6–48.6) 21.0 (7.0–35.7)
70–79 6.8 (0–24.0) 4.2 (0–14.8) 12.8 (4.1–27.5) 7.7 (2.5–16.8)
80+ 1.3 (0–3.1) 0.6 (0–1.4) 3.6 (0–8.2) 1.7 (0–3.9)
Total 224.4 (198.5–275.5) 291.4 (260.6–346.6) 731.7 (482.1–1067.2) 901.1 (603.3–1307.9)
Note that column totals are independently modeled and may therefore not exactly match age-specific output summaries.
doi:10.1371/journal.pntd.0000868.t005
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their 25 day stay in hospital. Other costs such as costs incurred by
health providers were not estimated in this study since Kaliua is a
missionary hospital and most of the care providers are based on
voluntary basis. Table 2 shows how these indirect costs were
estimated for each individual patient. For the total number of 143
patients at Kaliua this would then come to US$ 9781.20.
Discussion
Findings of the present study show that the re-emergence of
HAT in Urambo district continues to impose a significant burden
on health care systems as well as communities affected by the
disease. The study utilized datasets from hospital records
combined with estimates of under-reporting of T. b. rhodesiense
HAT in the district. The disease is severely neglected and does not
appear among the top priority diseases in any of the disease
endemic districts of Tanzania. Notably, the sporadic nature of
zoonotic HAT results in cases being recorded as other conditions
in hospital reports, health-care seeking for HAT can be prolonged
and frustrating [25] and many cases are not reported at all because
the affected patients fail to reach health facilities. This study
demonstrates the importance of conducting disease-specific
burden assessments in local settings [10] as they provide useful
epidemiological data that can be very useful in the planning,
prioritisation and proper allocation of limited resources in rural
areas.
The present study showed that nearly L of HAT cases
presented to health facilities in late stage of the disease, and almost
all (98%) most presented passively. Late stage presentation has
serious consequences; delays in seeking care result in reduced
chance of complete cure and late presentation increases the risk of
drug-associated adverse effects and the chances of treatment
failure which can both result in death [26]. Late stage HAT
patients suffer a much greater burden per episode and enormous
stigma as the disease may be mistaken for AIDS because both
diseases share clinical similarities. One explanation for late
hospital presentation is that patients spent much of the early stage
seeking health support from alternative sources and only after
failing to recover do they decide to seek referral medical attention
[25,26]. There are no effective traditional treatments for HAT and
HAT drugs are not available in any pharmacies.
Evidence shows that people often seek basic health services from
more than one source, including local drug stores and occasionally
traditional healers [25,26]. These studies observed that about 20%
of the communities living along the Tanzanian coast used no
health services at all - an interesting finding since communities
living along the coast may be considered to have a higher level of
awareness on health matters and also a better health services as
compared to most of the rural communities in remote areas of
western Tanzania where the present study was conducted [27].
This paper presents the first assessment of the burden of
rhodesiense HAT for Tanzania and only the second for East Africa.
Some studies on the burden of other neglected diseases and
zoonoses have been undertaken for Tanzania including the
burden of brucellosis [28]. Its findings which are consistent with
ours, both diseases show high burden that impact on local health
systems as well as communities.
Estimating disease specific burdens for individual conditions can
be useful, particularly when such studies use local data and can be
applied at the local level. Assessments do not require much
additional resource at the local level, while the results can inform
local systems with regard to disease prioritisation. Improvements
in record keeping should be a priority for local health facilities
wishing to improve the evidence-base for resource-allocation
decisions.
Previous burden of disease studies conducted in Tanzania
estimated that the country loses 10 million years of life annually
through illness and death. This amounts to four months of life lost
per year for every man, woman and child in the country [29]. Our
study also shows that families incur very substantial costs to
maintain their sick family members in the health system while
being treated for HAT. HAT patients require assistance with
almost all activities of daily living [25], and the majority of the
villages from which HAT patients arise are located far from the
treatment centres. The distance to health facilities has been
associated with serious delays in seeking health care services
[25,30]. It is clear that families with HAT patients will require
substantial financial capacity to cover transport costs as well as
maintain their patients in hospital for a prolonged duration.
The majority of affected communities are poor and have other
priority health conditions to attend to (infectious diseases as well as
non communicable diseases). Evidence from other rural areas of
Tanzania suggests that some communities could not afford a user
fee even as small as TZS 500 (approximately US$ 0.50) which
represents the charge for a basic laboratory investigation [31]. The
majority of families living in rural communities live below the
poverty line. Studies conducted in rural districts of Tanzania
during 1990–1996 suggested that 26% of rural communities were
Table 6. DALYs due to T.b.rhodesiense sleeping sickness in Urambo assuming the absence of AIDS/HIV pandemic.
Age of onset
(years)
DALYs with 0%
under-reporting and
no age weighting
DALYs with 0%
under-reporting and
with age weighting
DALYs with 45%
under-reporting and
no age weighting
DALYs with 45%
under-reporting and
with age weighting
0–4 1.2 (0–5.9) 0.5 (0–2.4) 33.8 (0–79.1) 52.4 (0–128.7)
5–14 149.4 (147.5–151.7) 204.1 (201.9–206.7) 176.8 (147.5–231.8) 194.9 (150.0–260.2)
15–29 35.9 (0–73.7) 48.9 (0–99.1) 234.6 (0–382.9) 349.9 (0–530.7)
30–44 18.4 (0–49.2) 23.1 (0–63.5) 108.1 (0–200.2) 159.8 (0–312.1)
45–59 10.5 (0–37.4) 10.7 (0–38.5) 65.7 (0–125.9) 95.9 (0–188.4)
60–69 8.0 (0–23.1) 6.2 (0–17.6) 31.3 (0–56.8) 44.2 (0–81.2)
70–79 1.4 (0–5.6) 0.8 (0–3.4) 8.9 (0–18.8) 12.9 (0–41.3)
80+ 0.9 (0–3.3) 0.4 (0–1.5) 3.2 (0–7.7) 4.4 (0–12.5)
Total 205.1 (147.5–273.0) 271.8 (205.1–349.9) 585.7 (17.5–1029.8) 805.5 (150.0–1550.1)
doi:10.1371/journal.pntd.0000868.t006
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in rural communities to spend such huge amount of money for
diagnosis of a family member is a serious financial burden. That
burden is likely to be more severe if the patient is the bread-
winner, as other family members will need either to do their work
on the farm or produce earnings to cover the gap caused by the
sick family member - not an easy task for rural settings where
employment is almost non-existent. Even if a HAT patient obtains
treatment, full recovery takes several months before a patient can
return to productive activities. In some cases patients may develop
serious long term or even permanent complications.
Several other authors have associated household income and
disease burden. A study conducted in Tanzania suggests that the
majority of the rural population suffers the combined burden of
diseases as most of the socio-economic activities carried at the
household level does not provide sufficient resource to cover their
basic health needs [33]. In Kenya, households could not afford to
buy a mosquito net to protect themselves or their family members
from malaria [34]. The first study of its kind to look at patients’
costs for HAT [35] estimated that patients spent the equivalent 1.5
months of income on costs, rising to nearly a quarter of a year’s
income if their time off work were included. For HAT, in the
Democratic Republic of Congo (DRC) it was found that
household incomes were so limited and the costs of HAT
treatment was considered to be so high that this was likely to
compromise the timely receipt of medical care [35]. In DRC,
patients’ average financial costs came to 5 months of income and
were as high as 10 months for some individuals. For families living
on less than US$ 1 per day in Tanzania, the cost of US$ 68.40 of
indirect non-medical costs plus US$ 25.50 of direct medical costs
per patient represents a similar proportion of income.
Patients and their family members with in a household often
take a long time to prepare for receiving health care and, in most
cases, such preparations depend on the solidarity of family
members and sometimes even community support [36]. Similarly,
household members take time to ready themselves and to mobilize
resources, before they seek HAT treatment on behalf of or
accompany [12,36]. In DRC it was observed that despite the
communities’ acceptance of active screening, the introduction of a
‘symbolic’ card fee was a major obstacle to treatment-seeking
behaviour [37]. This is likely to cause very serious consequences
for the household and may even compromise other family
commitments such as provision of basic education to school
children and even food provision to the rest of the family
members.
Our study also observed that the high disease burden of HAT
was largely attributed to high levels of disease under-reporting in
Urambo, which suggested that for every reported case of HAT
nine went un-reported [18]. Previous under-reporting studies in
Uganda estimated that for every 10 reported cases of HAT, 7 went
unreported, and, since untreated patients die, this meant that for
every HAT death reported to health systems, twelve others went
undetected [12]. Our studies also observed that HIV/AIDS
pandemic may have contributed to increase the burden of HAT in
Tanzania. Despite health reforms in Tanzania, expecting districts
to move from managing diseases to managing health systems from
an equity perspective is thought to be unrealistic [38]. The poorest
societies carry the heaviest burden of diseases and it is therefore
difficult for any health system to target the very poor accurately.
A recent study [32] observed that poorer families were less
active and effective in seeking health care than their relatively
wealthier counterparts even in rural societies that were assumed to
be uniformly poor. Despite Tanzania having the higher health
care seeking rates than many countries in sub-Saharan Africa,
health inequalities between the very poor and wealthier families
were obvious [38]. Members of better off families had higher
chances of obtaining suitable treatment once ill, than did those
from poor families.
There are some inherent limitations of using the decision tree
model for under-reporting in Tanzania that was originally
designed for Uganda. The data used to construct that model
were derived from an area with better health coverage and better
equipped health facilities [11] than in the area of Tanzania where
this study was conducted, where most health facilities do not have
even basic diagnostic equipment such as microscopes.
One of the major control challenges for HAT is the resurgence of
both the gambiense and rhodesiense forms of the disease, which has
been observed for rhodesiense in Tanzania as well as in many other
disease endemic countries of sub-Saharan Africa. Some of the
recent examples of these resurgences have been reported in several
countries [14,15,39,40], and there have also been reports of the
occurrence ofnew fociofHATinmany areasofsub-Saharan Africa
including Uganda and Tanzania [41,42]. This resurgence was
linked to a lack of adequate knowledge regarding disease trends as
well as of the controloptions in many of the affectedcommunities as
well among some policy makers [7,43]. This in turn was linked to
the lack of sufficient resources to sustain regular surveillance
activities. This stresses the urgent need for disease specific burden
estimation in such communities, as it will allow proper allocation of
the limited available resources in poor communities. Zoonotic HAT
affects both rural communities as well as the animals. Previous
studies observed that the lowest level of effective health seeking
behaviour was observed among livestock keepers [30]. Control
needs to be targeted at both humans and animals and needs to be a
shared responsibility between medical and veterinary sectors [44].
Being one of the most neglected diseases, in most cases HAT is
not considered an important disease in most of the affected
communities as there is a tendency for policy makers to rank the
disease according to their importance in the communities simply
by looking at national mortality figures. Findings from our study
demonstrated that HAT consumes a very significant proportion of
workforce resource, time and hospital space. Also the results of this
study demonstrated the importance of conducting disease-specific
burden studies, particularly in rural settings rather than general-
izing using regional or national figures, reinforcing the conclusions
of earlier work [10]. There is a need to target the limited available
resources more efficiently so as prevent future outbreaks. In
deciding areas requiring prioritisation it is important to use
estimates from community perspectives. Local burden of disease
estimates are important aspects as they provide good epidemio-
logical data which can be used for timely planning and proper
resource allocation in most of the local health care settings and
inform disease prioritisation in rural settings.
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